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A B S T R A C T
Background
The hepatitis C virus (HCV) infection affects about 2% of the world’s population and can cause chronic liver infection and persistent
long-term sequelae such as cirrhosis and liver cancer.
The prevalence of HCV infection among people on haemodialysis is often higher than the general population. The virus is easily
transmitted parenterally, and blood transfusions have previously played a significant role in transmission; however, erythropoietin
therapy has reduced the need for transfusions, and coupled with improved screening of donated blood, has significantly decreased
transmission by transfusion. Although control of hospital-acquired infection has improved with the advent of biosafety measures,
stopping HCV transmission in haemodialysis units remains challenging.
Isolating people infected with HCV involves physical separation from others to limit direct or indirect transmission and includes a
number of strategies during dialysis. The evidence for isolating people infected with HCV during haemodialysis is sparse with some
inconsistencies.
Objectives
To evaluate the benefits and harms of isolation of HCV-infected patients during haemodialysis on the transmission of HCV to other
patients.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 26 November 2015 through contact with the Information
Specialist using search terms relevant to this review. We also searched the Latin American and Caribbean Health Sciences Literature
Database (LILACS) (1982 to 2015), Web of Science Conference Proceedings Citation Index-Science (CPCI-S, 1990 to 2015), ProQuest
Dissertations & Theses Database (1990 to 2015), and Open Grey (1990 to 2015).
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Selection criteria
We included randomised controlled trials (RCTs), quasi-RCTs and cluster RCTs evaluating the clinical benefits and harms of isolating
HCV-infected patients during haemodialysis on the transmission of HCV to other patients. We considered incidence of dialysis-
acquired HCV infection, all-cause mortality, and adverse effects associated with isolation as the primary outcomes.
Data collection and analysis
Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95%
confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) or standardised mean difference (SMD) and 95% CI
for continuous outcomes.
Main results
Only one study, which included 12 centres was identified: four centres used dedicated haemodialysis machines for HCV-infected
patients and eight centres used non-dedicated machines. The total number of patients enrolled was 593. One centre was excluded
after randomisation. Random sequence generation was not described and allocation concealment was not performed. Participants and
personnel were not blinded and blinding of outcome assessors was not reported. Only 74.5% of the patients were followed for 9
months; and 47.3% were followed for an additional 9 months. The authors only reported one outcome, measuring the difference in the
incidence of HCV in both groups. The authors did not consider the exposure time, to determine the adjusted rate of seroconversion
risk/patient-year.
The study reported that the incidence of HCV infection during the first follow-up period (9 months) was 1.6% in the dedicated
group, and 4.7% in the non-dedicated one (446 patients analysed out of 593 randomised; RR 0.34, 95% CI 0.11 to 1.07). During the
second follow-up period (18 months) the incidence was 1.3% in the dedicated group and 5.8% in the control (281 patients analysed
out of 593 randomised; RR 0.22, 95% CI 0.05 to 1.02). Therefore, we found no differences in terms of the number of participants
developing HCV infection when comparing the dedicated group with the usual care. Moreover, the evidence was of very low quality,
which means that we have very little confidence in the effect estimate.
Authors’ conclusions
The benefits and harms of isolation of HCV-infected patients during haemodialysis on the transmission of HCV to other patients are
uncertain. Evidence from one short-duration cluster-randomised study with a high risk of bias did not find differences in terms of the
number of participants developing HCV infection when comparing the use of dedicated haemodialysis machines for HCV infected
patients with the use of non-dedicated machines.
P L A I N L A N G U A G E S U M M A R Y
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
What is the issue?
The hepatitis C virus (HCV) is easily transmitted intravenously, such as blood transfusions and the use of haemodialysis. It can cause
a persistent infection and chronic liver disease. The frequency of HCV is higher among people on haemodialysis than the general
population; and is associated with increased risk of death from heart disease and liver. We wanted to find out if the isolation of people
with HCV during haemodialysis (using a different room, machines or dedicated staff, a specific shift) was effective in limiting the direct
or indirect transmission of the virus to non-infected patients.
What did we do?
We conducted an extensive literature search to November 26, 2015, but only found one study looking at isolation as a strategy for
controlling the transmission of HCV infection.
What did we find?
This one study included 12 centres (593 patients). Four centres assigned HCV-infected patients to a dedicated haemodialysis machine
and eight centres did not. This study reported the incidence of HCV in haemodialysis patients decreased with the use of dedicated
machines; however it was not possible to determine the benefits and harms associated with isolation, cost, or mortality from the disease.
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Conclusions
There is insufficient evidence, but additional studies would help clarify the role of isolation to reduce the transmission of HCV in
haemodialysis patients.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should pat ients with HCV be isolated in haemodialysis units for controlling the transmission of HCV?








Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with isolation
Incidence of HCV infec-
t ion (9 months)




Very low quality of evi-
dence due to high risk
of bias and imprecision47 per 1.000 16 per 1.000
(5 to 50)
Incidence of HCV infec-
t ion (18 months)




Very low quality of evi-
dence due to high risk
of bias and imprecision58 per 1.000 13 per 1.000
(3 to 59)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
























































































































B A C K G R O U N D
Description of the condition
Hepatitis C virus (HCV) infection affects approximately 3% of
the global population, or about 170 million people (Lee 2014).
HCV causes persistent infection and chronic liver disease; long-
term sequelae include cirrhosis (30%) and liver cancer (1% to 5%)
(Hsu 2015; Webster 2015).
Extrahepatic manifestations of chronic HCV infection are consid-
ered to be of immunologic origin and include cryoglobulinaemia,
membranoproliferative glomerulonephritis, (Morales 2012) and
porphyria cutanea tarda.
Prevalence of HCV infection in haemodialysis patients is usually
higher than in the general population (Fabrizi 2012). The overall
incidence rate of HCV infection is 1.47/100 patient-years; 4.44/
100 patient-years in low- to middle-income countries, and 0.99/
100 patient-years in high-income countries (Su 2013). Prevalence
ranges from less than 5% in most Northern European countries
(Fissell 2004; Schneeberger 2000) to over 70% in many parts of
the world, including countries in Asia, Latin America and North
Africa (Sun 2009; Vladutiu 2000). However, the prevalence of
HCV in European dialysis centres declined sharply in the early
2000s. This was attributed to reduced risk of hospital-acquired in-
fection and occupational HCV infection (Jadoul 2004), increased
mortality rates, and stabilisation of the incidence of acute HCV
infection (Espinosa 2004). Falling prevalence rates emphasise the
importance of adhering to recommended infection control pre-
cautions and virological follow-up to detect anti-HCV antibod-
ies using sensitive, specific new-generation serological tests (Saune
2011).
HCV-infected haemodialysis patients are at increased risk of liver
or cardiovascular disease-related death compared with non-in-
fected patients (Fabrizi 2012). HCV infection is associated with
increased morbidity and mortality in kidney transplant recipients
(Batty 2001; Butt 2007; Mahmoud 2004). Anti-HCV-positive
patients on dialysis are at increased risk compared with anti-HCV-
negative patients.
Description of the intervention
Isolating HCV-infected patients (or patients waiting HCV screen-
ing results) during haemodialysis is defined as physical segregation
from others for the express purpose of limiting direct or indirect
transmission of HCV. Isolation policies may include strategies for
HCV-infected patients with different grades of intensity, such as
use of a dedicated dialysis machine, personnel, room, or shift, or
other barrier precautions (such as aprons, gowns, or gloves), by
healthcare professionals attending these patients. These strategies
may be implemented in combination.
How the intervention might work
HCV is easily transmitted parenterally and its control has therefore
been a challenge in dialysis settings (Natov 2005; Su 2013). More
recently erythropoietin therapy, which reduces requirements for
transfusions, together with more sensitive tests to detect HCV in
donated blood, have significantly reduced transmission via trans-
fusion (Marwaha 2014). The post-transfusion risk has been cal-
culated at around 0.0001% in the USA (i.e. 1 blood transfusion
in 1 million units of blood), with similar dramatic improvements
in the viral safety of blood in other western countries (Selvarajah
2012).
The WHO has estimated an overall prevalence of 3% for HCV
infection in the global population, but there is a wide geographic
variability: fewer than 5% of people in most northern European
countries are infected, close to 10% in southern Europe and the
USA, and estimates range from 10% to 50% and up to 70% in
many low- to middle-income countries. HCV infection incidence
has however decreased to less than 1.2% of people in high-income
countries (Espinosa 2004; Finelli 2005; Jadoul 2012).
This reduction was initially attributed to decreased rates of post-
transfusion infection (Djordjevic 2000; Valtuille 2002), but it was
later ascribed to other infection control measures used to prevent
hospital-acquired infection rates in dialysis units. Prevalence of
HCV infection among people on haemodialysis is generally below
10% in most countries, but may be higher (> 20%) where social
crisis, war, or economic downturn exist (Ali 2011; Selm 2010;
Voiculescu 2010). In these situations, maintenance of chronic
haemodialysis programs is highly challenging, and infection con-
trol programs are difficult to maintain.
In spite of reduced rates of infection, HCV transmission in
haemodialysis units remains an unsolved problem. Despite ad-
vances in screening blood products for HCV people on haemodial-
ysis it remains at a higher risk of infection than in the general
population (Ozer Etik 2015)
HCV seroconversion (change from anti-HCV negative to anti-
HCV positive) has been detected in patients who were never trans-
fused (Agarwal 2011) therefore other mechanisms of transmission
occur in dialysis units. Shared haemodialysis machines (Elamin
2011; Sartor 2004) and reprocessing of dialysers from people with
HCV have been linked to HCV transmission (Bashiri 2013).
Other factors include physical proximity to an infected person and
sharing personal items (Al-Ghamdi 2004; Fabrizi 2008); break-
down in standard infection control practices, including improper
handling and preparation of medications (Alter 2008; CDC 2009;
Samandari 2005; Thompson 2009; Williams 2004); poor envi-
ronmental cleaning (CDC 2009; Girou 2008; Kamili 2007; Patel
2010; Thompson 2009) and basic hygiene practices (Alfurayh
2000; Patel 2010); staff numbers and workload (Arenas 2005;
CDC 2009; KDIGO 2008; Patel 2010; Shimokura 2011).
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Why it is important to do this review
The evidence for or against the use of isolation of HCV-infected
patients during haemodialysis is weak and certain inconsistencies
exist regarding the recommendations for its use among different
guidelines. The centres for Disease Control and Prevention (CDC
2001; Mbaeyi 2013) published guidelines to prevent the transmis-
sion of HCV and other infections among haemodialysis patients,
but did not recommend the isolation of HCV-infected patients.
KDIGO 2008 stated that haemodialysis units should ensure im-
plementation of and adherence to strict infection-control proce-
dures designed to prevent transmission of blood-borne pathogens,
including HCV, but isolation of HCV-infected patients was not
recommended as an alternative to strict infection-control proce-
dures (unless in cases of continued hospital-acquired transmission,
where a local isolation policy may be deemed necessary). The UK
Renal association stated that patients with HCV patients do not
need to be dialysed in a segregated area, however more experienced
staff should be assigned. If nosocomial transmission continues to
occur, despite reinforcement and audit of the precautions, a local
segregation policy may be deemed necessary (Geddes 2011)
The European Best Practice (ERBP) Work Group considers that
implementation of universal hygienic measures should be the stan-
dard of care. Isolation of positive patients could be considered, but
only if this practice does not have a negative impact on the im-
plementation and reinforcement of basic hygienic measures in the
unit as a whole (Covic 2009). Some investigators support isolat-
ing patients with HCV infection in a specific haemodialysis room
(Fabrizi 2008), or suggest that the no isolation policy should not
be generalised. Whether or not HCV-positive patients should be
isolated is still debated, particularly since isolation policies to con-
trol HCV infection transmission in haemodialysis units involves
significant logistic problems that should be considered.
O B J E C T I V E S
This review aimed to evaluate the benefits and harms of isolation of
HCV-infected patients during haemodialysis on the transmission
of HCV to other patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs
in which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods), and cluster RCTs and cluster quasi-RCTs (where cen-
tres rather than individual patients were randomised), looking at
isolation of HCV-infected patients during haemodialysis were el-
igible for inclusion.
Types of participants
All patients (adults and children) undergoing maintenance
haemodialysis and dialysed in a haemodialysis centre (e.g. hospital
unit, outpatient clinic) were eligible for inclusion.
Types of interventions
Intervention group
Any strategy targeting the isolation during haemodialysis of HCV-
infected patients or patients waiting HCV screening results was
eligible. Isolation was defined as the physical segregation of these
patients from others with the express purpose of limiting direct or
indirect transmission of HCV to other patients. Isolation policies
could include a number of strategies with different grades of in-
tensity, such as the use of a dedicated dialysis machine, personnel,
room or dialysis shift.
Control group
We considered any control group that enabled comparison to de-
termine the relative effect of the isolation strategy as eligible for
inclusion. Studies comparing two types of isolation strategies were
also eligible.
Types of outcome measures
Primary outcomes
• Incidence of dialysis-acquired HCV infection
• All-cause mortality
• Adverse effects associated to the isolation strategy (such as
negative effects on patient mental well-being, or adverse effects
related to supportive care failures).
Secondary outcomes
• Incidence of dialysis-acquired non-HCV infections
• Patient satisfaction with treatment, measured with a
validated tool
• Isolation costs.
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Search methods for identification of studies
Electronic searches
We searched Cochrane Kidney and Transplant’s Specialised Reg-
ister to 26 November 2015 through contact with the Information
Specialist using search terms relevant to this review. The Cochrane
Kidney and Transplant Specialised Register contains studies iden-
tified from the following sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based
on Cochrane Kidney and Transplant scope. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts are available in the Specialised
Register section of information about the Cochrane Kidney and
Transplant.
We searched the following electronic databases.
1. Latin American and Caribbean Health Sciences Literature
Database (LILACS) (1982 to 2015)
2. Web of Science Conference Proceedings Citation Index-
Science (CPCI-S, 1990 to 2015) (accessed via ISI Web of
Science)
3. ProQuest Dissertations & Theses Database (1990 to 2015)
4. Open Grey (1990 to 2015).
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles and relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and abstracts
of studies that may be relevant to the review. Titles and abstracts
were screened independently by two authors, who discarded stud-
ies that were not applicable; however, studies and reviews thought
to include relevant data or information on studies were retained
initially. Two authors independently assessed retrieved abstracts,
and if necessary the full text, of these studies to determine which
satisfied the inclusion criteria.
Data extraction and management
Data extraction was to be carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals were to be translated before assessment.
Where more than one publication of one study existed, reports
were to be grouped together and the publication with the most
complete data used in analyses. Where relevant outcomes were
only published in earlier versions these data were to be used. Any
discrepancy between published versions was to be highlighted.
Assessment of risk of bias in included studies
The following items were to be independently assessed by two
authors using the risk of bias assessment tool (Higgins 2011a) (see
Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was recruitment bias adequately prevented?
• Were baseline imbalances (in terms of either the clusters or
the individuals) adequately addressed?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
• Was the study analysed by correct statistical methods (i.e.
taking the clustering into account)?
Measures of treatment effect
For dichotomous data and for counts of rare events and rates (dial-
ysis-acquired HCV infections, dialysis-acquired non-HCV infec-
tions, mortality due to dialysis-acquired infections, all-cause mor-
tality, adverse effects) we planned to report risk ratios (RR); for
continuous data (patient satisfaction with treatment) we planned
to use the mean difference (MD) with 95% CI. Where different
scales were used to measure continuous outcomes, we planned to
calculate a standardised mean difference (SMD).
Unit of analysis issues
We planned to include cluster RCTs, and when possible, extract
effect measures and standard error rates from an analysis taking
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clustering into account. If that was not possible, we planned to
extract the number of clusters and estimate the intra-cluster cor-
relation coefficient to inform a reliable analysis. If this was not
possible, we planned to disregard the clustering and investigate
the effect of this in a sensitivity analysis (Deeks 2011).
Dealing with missing data
We planned to extract data for intention-to-treat analyses (ITT)
and contact authors if required information was missing. Where
ITT analysis was not possible, we planned to extract data from an
available case analysis and assess the risk of bias from attrition.
Assessment of heterogeneity
We planned to analyse heterogeneity using a Chi² test on N-1
degrees of freedom, with an alpha of 0.05 used for statistical sig-
nificance, and the I² statistic.
Assessment of reporting biases
We did not expect that a sufficient number of studies would be
identified to create a useful funnel plot. Assessing reporting bias is
difficult, but we planned to note whether outcomes that we con-
sidered important were reported. We planned to contact authors
about possible unpublished outcomes.
Data synthesis
We planned to use a random-effects model and to express the re-
sults as both relative risks and number-needed-to-screen to achieve
the relevant outcomes, both beneficial and harmful.
Subgroup analysis and investigation of heterogeneity
We planned to perform the subgroup analyses
1. Mean duration of the haemodialysis treatment
2. The degree of missing primary outcome data
i) High prevalence of HCV in the haemodialysis unit:
studies implemented in a context of high HCV prevalence (<
5%) versus non-high HCV prevalence (≥ 5%)
3. Outbreak situation: studies implemented when healthcare
associated infection (any pathogen) were noted to be increasing
or to exceed a recognised benchmark versus non outbreak
situation
4. Types of isolation.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influence
of the following factors on effect size.
• Repeating the meta-analysis to assess the effect of excluding
studies with high risk of bias
• Exploring the impact of the assumptions taken in the
available case analysis by performing a sensitivity analysis with
imputation of missing data
• Assessing the effect of the statistical model chosen for meta-
analysis (fixed-effect model versus random-effects model)
• Repeating the meta-analysis to assess the effect of including
only studies with allocation to interventions at the group level
(cluster designs) (Ukoumunne 1999).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The combined search of MEDLINE, EMBASE and CENTRAL
identified a total of 126 articles, of which 125 were excluded.
1. Twenty one records were duplicates
2. After reviewing the abstracts, 93 records were excluded
because they did not meet our inclusion criteria
3. After full text review an additional 11 records, which were
not RCTs, were excluded.
We therefore included one study enrolling 593 patients (
Shamshirsaz 2004). A flow chart of the study selection process is
shown in Figure 1
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Figure 1.
Included studies
Shamshirsaz 2004 was a prospective RCT evaluating the effect
of dialysis machine separation in reducing HCV transmission to
haemodialysis patients. Selected centres were randomly divided
into dedicated and non-dedicated haemodialysis machine groups.
Positive cases were confirmed by RT-PCR. Information regarding
age, sex, occupation (health care personnel, surgeons and dentists),
HCV-infected relatives, previous peritoneal dialysis, surgery dur-
ing last 2 months, duration of haemodialysis, number of blood
product transfusions, history of organ transplantation, and the
causes of ESRD was collected. Outcomes included incidence of
HCV infection in both groups.
Patients were dialyzed for 4 to 4.5 hours, 2 or 3 times/week, using
standard haemodialysis techniques. All included haemodialysis pa-
tients were HIV and hepatitis B surface antigen (HBsAg) negative.
Dialysis membranes were low pressure and used only once and
haemodialysis machines were bleached and rinsed between dialysis
sessions according to the manufacturers’ instruction. All machines
were located in dialysis wards and not in separate rooms for both
groups. Patient to staff ratio in the dedicated and non-dedicated
groups was not statistically different (3.1 and 3.4 respectively) and
all staff members were negative for anti-HCV. Education courses
hygiene guidelines the CDC were conducted for all personnel in-
volved in patient care, a checklist of the practice was used. In all
centres the patients had specific dialysis place. It was specified how
often the tests were performed HCV patients during the study or
whether this was routinely carried out.
The patients were followed for 9 months (first follow-up popula-
tion) and 281 patients who remained within the study were fol-
lowed for an additional 9 months (second follow-up population).
See Characteristics of included studies.
Excluded studies
Eleven studies were not RCTs (Agarwal 2009; Barril 2003; Gallego
2006; Garcia-Valdecasas 1994; Huang 1995; Mohamed 2010;
Ross 2009; Saxena 2003; Shebeb 2006; Valtuille 1998; Yang 2003)
Risk of bias in included studies
See risk of bias in Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across one included study.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for one included
study.
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Allocation
This study did not describe the use of a random number table to
generate the allocation sequence. Allocation concealment was not
performed
Randomisation was performed by dialysis centre. It was a clus-
ter RCT, which included four centres (dedicated) compared with
eight centres (non-dedicated).
Blinding
Participants (patients and investigators) were not blinded. Blind-
ing of outcome assessors was not reported.
Incomplete outcome data
Only 74.5% (446/593) of the patients were followed for 9 months,
and 47.3% (281/593) were followed for an additional 9 months.
One centre was excluded after randomisation causing a deviation
from protocol.
Selective reporting
The authors only reported one outcome, measuring the difference
in the incidence of HCV in both groups. No secondary outcomes
were reported.
The authors did not consider the exposure time, to determine the
adjusted rate of seroconversion risk/patient-year.
Other potential sources of bias
The assessments of the risk of bias domains relative to cluster
designs are detailed in the risk of bias table (see Characteristics of
included studies).
Effects of interventions
See: Summary of findings for the main comparison Dialysis
machine separation versus usual care
Incidence of dialysis-acquired HCV infection
Shamshirsaz 2004 reported the incidence of HCV infection was
1.6% in the dedicated group and 4.7% in the non-dedicated one
(Analysis 1.1 (1 study 446 participants): RR 0.34, 95% CI 0.11 to
1.07) during the first follow-up period (9 months). During the sec-
ond follow-up period (18 months), the incidence was 1.3% in the
dedicated group and 5.8% in the non-dedicated group (Analysis
1.2 (1 study, 281 participants): RR 0.22, 95% CI 0.05 to 1.02).
Therefore, we found no differences in terms of the number of
participants developing HCV infection when comparing the ded-
icated group with the usual care. Moreover, the evidence was of
very low quality, which means that we have very little confidence
in the effect estimate and that the true effect is likely to be sub-
stantially different from the estimate of effect.
All-cause mortality
Mortality was not reported.
Adverse effects
Adverse effects associated with the isolation strategy were not re-
ported.
Incidence of dialysis-acquired non-HCV infections
Incidence of dialysis-acquired non-HCV infections were not re-
ported.
Patient satisfaction with treatment
Patient satisfaction with treatment was not reported.
Isolation costs
Isolation costs were not reported.
D I S C U S S I O N
Summary of main results
Only one study meeting our inclusion criteria was identified
(Shamshirsaz 2004). This study selected haemodialysis centres,
one by one to reach a total number of 593 patients (12 centres).
Selected centres were randomly divided in to dedicated and non-
dedicated haemodialysis machine groups, including 297 patients
in the dedicated group (4 centres) and 296 patients in the non-
dedicated group (8 centres). This study found that the use of dialy-
sis machines dedicated for HCV infected individuals, as compared
with the use of non-dedicated dialysis machines, made no differ-
ence in terms of reducing the incidence incidence of HCV infec-
tion during the first (9 months) or second (18 months) follow-up
periods. The quality of the evidence was very low (see Summary
of findings for the main comparison).
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This study did not report any of our other primary outcomes
of interest (all-cause mortality, adverse effects associated with the
strategy of isolation).
Overall completeness and applicability of
evidence
We planned to include patients (adults and children) undergoing
maintenance haemodialysis and dialysed in a haemodialysis centre
and assess whether strategies isolation machine, room, staff or
dialysis shift influence the transmission of hepatitis C. Our search
just found one study where the separation of machines is evaluated
as a form of isolation.
Consideration should also be given to both the prevalence of hep-
atitis C and the geographical region as this may influence the possi-
bility of seroconversion. Regions with high prevalence may require
isolation combined strategies: room, machine, and personnel. No
costs are included for the isolation strategy.
Methods of randomisation were unclear, participants and patients
were not blinded, so that the results of this study must be consid-
ered with some caution. Confirmatory research is required. Any
further studies conducted in this area must be well designed RCTs
assessing these primary outcomes.
Quality of the evidence
This review is based on the evidence of one RCT (Shamshirsaz
2004) that included a total of 12 haemodialysis centres (593 pa-
tients) divided into a group of dedicated dialysis machines involv-
ing four centres: 297 patients, 267 negative and 30 positive for
HCV and a group of centres with non-dedicated machines: 8 cen-
tres: 296 patients, 275 negative and 21 positive for HCV.
The authors did not disclose the details of the method of randomi-
sation, participants and patients were not blinded, and blinding
of outcome assessors was not reported. The authors decided to ex-
clude, after randomisation, one of dialysis centres in the non-ded-
icated group due to non-adherence to CDC hygienic guidelines
early in the study. There was a high risk of bias due to incomplete
outcome data: only 74.5% of patients were followed for 9 months,
and 47.3% were followed for an additional 9 months. In addition,
the estimation of the effect of the intervention was imprecise. This
makes the quality of evidence very low (see Summary of findings
for the main comparison).
Potential biases in the review process
We followed the Cochrane Collaboration guidelines for conduct-
ing this systematic review and meta-analysis. Strengths of our re-
view include the searching of several databases. Study selection,
assessment of risk of bias, and data extraction were performed by
two authors, which reduced the risk of error and bias. Although
efforts were made to collect relevant data, the possibility of miss-
ing data cannot be excluded. Publication bias remains a possible
source of important bias. Meanwhile, interpretation of the result
should be done with extreme caution.
Agreements and disagreements with other
studies or reviews
We are not aware of any other systematic review on this topic;
many authors have reported some reduction (but not full preven-
tion) of HCV transmission in haemodialysis, and after the adop-
tion of an isolation policy, most of the studies have compared their
results with their own historical control (before-and-after). Thus,
it is unclear whether the reported improvement resulted from the
adoption of an isolation policy or rather from the simultaneous
raising of awareness and reinforcement of the application of hy-
gienic precautions. These isolation policies include: implementing
the isolation of a room (Agarwal 2009; Barril 2003); using exclu-
sive machines (Garcia-Valdecasas 1994); and isolating machines,
room and staff (Gallego 2006; Huang 1995; Saxena 2003); and
Mohamed 2010, Ross 2009 and Shebeb 2006, compared isolation
versus universal precautions. In all cases isolation was found to
decrease the rate of seroconversion. In addition, Yang 2003 con-
ducted a study with three sets of patients: one set without isola-
tion, a second set with a dedicated area and a dedicated machine
in the same room and a third set of patients isolated in a separate
room, and showed that isolation in a different room was better
than dedicated machines.
In contrast, a DOPPS multicentre study concluded that isolation
does not protect against transmission of HCV in haemodialysis
patients (Fissell 2004). A prospective observational study by Jadoul
1998 showed a reduction from 1.4% to 0% of the annual incidence
of HCV seroconversion. They have reported a reduction of HCV
transmission after the reinforcement of basic hygienic precautions,
without any isolation measures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Data from robust RCTs are not available to allow conclusions to
be drawn about the relative effectiveness of isolation as a strategy
to control HCV transmission in haemodialysis units. Therefore,
the benefits and harms of isolation remain unknown.
Implications for research
Large, multicentre long-term RCTs of good quality are required to
answer the questions concerning the benefits and harms of isola-
tion of HCV-infected patients during haemodialysis. These stud-
ies should evaluate mortality, costs and complications associated
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with isolation. These studies should ensure the physical separation
of either the centre or room; these programs should have strict
isolation strategies in place that include staff as well as machines
dedicated to HCV-infected haemodialysis patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Shamshirsaz 2004
Methods • Study design: cluster RCT; they randomly selected centres one by one to reach a
total number of 593 patients (12 centres)
• Study duration: 2 years
• Duration of follow-up: 442 patients (254 cases in the treatment group and 192 in
the control group) were followed for 9 months. 281 patients (160 in the treatment
group and 121 in the control group) were followed for an additional 9 months
Participants • Setting: multi-centre
• Country: Iran
• ELISA III checked all patients for HCV antibody detection before enrolling in
the study, positive cases were confirmed by RT-PCR
• Number: 593 enrolled
◦
Treatment group: 297; 267 negatives and 30 positives by HCV
◦
Control group: 296; 275 negatives and 21 positives by HCV
• Mean age ± SE (years): treatment group (48.1 ± 0.9); control group (50.6 ± 1.0)
• Sex (% male): treatment group (59.9); control group (54.2)
• Exclusion criteria: not reported
Interventions Treatment group
• Centres with dedicated HD machines
• Dialysis membranes were low pressure and used only once and HD machines
were bleached and rinsed between dialysis sessions according to the manufacturers’
instruction. All machines were located in dialysis wards and not in separate rooms in
both groups.
Control group
• Centres with no dedicated HD machines
Outcomes • Incidence of HCV infection in both groups, to evaluate the effect of dialysis
machine separation on the spread of HCV infection
Notes • To prevent HCV transmission, educational courses were held for the staff to re-
emphasize the CDC hygienic guidelines
• Patients were dialyzed for 4 or 4.5 hours, 2 or 3 times/week, using standard HD
techniques, patient to staff ratio in the groups wasn’t statistically different (3.1 and 3.4
respectively) and all staff members were negative for anti-HCV
Risk of bias
Bias Authors’ judgement Support for judgement
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Shamshirsaz 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process
Randomisation was performed by dialysis
centre, it was a cluster randomised trial
which included four centres (intervention)
compared with eight centres (control)
Allocation concealment (selection bias) High risk Allocation concealment was not performed
Was recruitment bias adequately pre-
vented?
High risk Individuals were recruited to the trial af-
ter the clusters had been randomised (the
knowledge of whether each cluster is an ‘in-
tervention’ or ‘control’ cluster could affect
the types of participants recruited)
Were baseline imbalances (in terms of ei-
ther the clusters or the individuals) ade-
quately addressed?
High risk There were baseline imbalances between
the randomised groups, but finally they
were not controlled for at the design or
analysis stage of the study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk There was no blinding of participants or
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis was not per-
formed. There was an “available case analy-
sis” done with substantial departure of the
intervention received from that assigned at
randomisation
Only 74.5% of the patients were followed
for 9 months and 47.3% were followed for
an additional 9 months
They lost > 10% of their population
One centre was excluded after randomisa-
tion, causing a deviation from protocol
Selective reporting (reporting bias) High risk The authors only reported one result, mea-
suring the difference in the incidence of
HCV in both groups, based on that issued
its findings, did not have secondary out-
comes
The authors did not consider the exposure
time (i.e. years patients at risk) in determin-
ing the rate of seroconversion
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Shamshirsaz 2004 (Continued)
Was the study analysed by correct statisti-
cal methods (i.e. taking the clustering into
account)?
High risk “Comparisons between groups were made
by the chi square test method for categorical
variables and by the t test for quantitative
variables.”
The cluster-randomised trial was analysed
by incorrect statistical methods, not taking
the clustering into account
CDC - Centers for Disease Control and Prevention; HCV - hepatitis C virus; HD - haemodialysis; SE - standard error
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agarwal 2009 Cohort study 2003 to 2006, room isolation, HCV seroconversion from 42% in 1995 to 1998 (without
isolation) to 4% in 2003 to 2006 (with isolation)
Barril 2003 Cohort, multicentre study: 44 centres, room isolation, evaluate prevalence of hepatitis C and time, it divide
its population in 4 quartiles according prevalence of hepatitis C, after isolation they observe decrease of
seroconversion in all quartiles
Gallego 2006 Analytic study, comparing two periods of 1993 to 1995 in which isolation of machines for patients with
hepatitis C is applied, and where are 2 seroconversions and second period 1996 to 2003 applied isolation
room and staff, which do not show any seroconversion. Progressive decline observed prevalence of hepatitis
C in its population 30.5% vs 6.8%
Garcia-Valdecasas 1994 Analytic study, three rooms of dialysis: Room A: 27 patients and 6 HCV (+), Room B: 28 patients; 7 HCV
(+), Room C: 25 patients, 14 with HCV (+); No isolation: 1990, 1991 to 1992 isolation of machine only
in rooms A and B, isolation
Huang 1995 Prospective study, from April 1992, 32 patients negative for HCV, isolated machine and room, after 14.
2 + 3 months, a patient seroconverted, apparently associated with blood transfusion, seroconversion rate
14.6% versus 3.1% prior to isolation (historical data)
Mohamed 2010 Prospective study was conducted on 36 seronegative HD patients. All patients were managed with strict
application of infection control guidelines as well as isolation of HCV-positive patients. After five years of
follow-up, They found that the incidence of HCV seroconversion was zero
Ross 2009 Large prospective multicentre study was conducted. In the first and second rounds, 150 (5.2%) of 2909
and 114 (5.4%) of 2100 patients were anti-HCV positive, respectively, and 4% of individuals were viraemic
20% of these patients no nosocomial Hepatitis C transmission occurred during the observational period
suggests that the lack of HCV seroconversions was not only attributable to the isolation of HCV-infected
patients but also to the strict adherence universal hygienic precautions
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Saxena 2003 Retrospective study, In the first phase, 189 patients who were receiving maintenance HD from 1995 to
2000 were studied about prevalence of HCV. Phase II involved stringent isolation of anti-HCV positive
patients detected during phase, with dedicated space, dialysis equipment, and nursing staff from December
2000 to December 2001. Prevalence rate of 43.9% (83/189) and an annual HCV seroconversion rate of
6.8% were identified in this cohort. Only 2 new HCV seroconversions (1.01% (2/198)) were identified
after isolation
Shebeb 2006 This study compared strict adherence to the universal precautions and anti HCV seropositive patient
isolation. Three units: A: education intervention program, 30 patients and 12 staff personal, B: none of
the preventive measures were applied, 66 patients nursed by 16 staff C: had 67 patients nursed by 27 staff.
The incidence rate of anti HCV seroconversion decreased in unit A from (10% to 0%), and in unit C
from (24.4% to 10%), 6 months of the follow. It increased in unit B, where no measure was taken, from
10.5% to 16.7%
Valtuille 1998 Study applying extreme conditions of permeability to the dialysis membrane and avoiding the use of
heparin and dialysis bath. They obtained samples from the ultrafiltrate at the beginning of 18 HD sessions
carried out in 6 HCV RNA-positive patients. HCV RNA was detected by PCR in 3 (16.7%) ultrafiltrate
samples belonging to 1 of the patients. HCV genotype was the same as that found in positive ultrafiltrate
samples and in the serum corresponding to this patient
Yang 2003 Retrospective study, 325 HD patients from1993 to 2000 were included, isolation started after 1997.
Patients positive for either hepatitis B or C were clustered in 1 area. Anti-HCV-negative and HBsAg -
negative patients were assigned either to a segregated zone (Area 2) in the same room or to a separate
independent room (Area 3). Forty months after the implementation of the isolation policy, there was
significant reduction in the total prevalence (49.7 vs 31.7%) and incidence (9.1 vs 2.9 % patient-years) of
HCV infection
HBsAg - hepatitis B surface antigen; HCV - hepatitis C virus; HD - haemodialysis
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D A T A A N D A N A L Y S E S
Comparison 1. Dialysis machine separation vs Usual care




participants Statistical method Effect size
1 Incidence of HCV infection: 9
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Incidence of HCV infection: 18
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Dialysis machine separation vs Usual care, Outcome 1 Incidence of HCV
infection: 9 months.
Review: Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
Comparison: 1 Dialysis machine separation vs Usual care
Outcome: 1 Incidence of HCV infection: 9 months








Shamshirsaz 2004 4/254 9/192 0.34 [ 0.11, 1.07 ]
0.01 0.1 1 10 100
Favours isolation Favours usual care
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Analysis 1.2. Comparison 1 Dialysis machine separation vs Usual care, Outcome 2 Incidence of HCV
infection: 18 months.
Review: Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
Comparison: 1 Dialysis machine separation vs Usual care
Outcome: 2 Incidence of HCV infection: 18 months








Shamshirsaz 2004 2/160 7/121 0.22 [ 0.05, 1.02 ]
0.01 0.1 1 10 100
Favours isolation Favours usual care
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Renal Dialysis] this term only
2. MeSH descriptor: [Hemofiltration] explode all trees
3. dialysis or hemodialysis or haemodialysis in Trials
4. hemofiltration or haemofiltration in Trials
5. hemodiafiltration or haemodiafiltration in Trials
6. #1 or #2 or #3 or #4 or #5
7. MeSH descriptor: [Hemodialysis Units, Hospital] this term only
8. ((hemodialysis or haemodialysis or dialysis) and (centre* or centre* or unit* or department* or hospital* or
facilit* or clinic*)) in Trials
9. MeSH descriptor: [Outpatient Clinics, Hospital] explode all trees
10. MeSH descriptor: [Ambulatory Care Facilities] explode all trees
11. #7 or #8 or #9 or #10
12. MeSH descriptor: [Hepatitis C] explode all trees
13. MeSH descriptor: [Hepacivirus] this term only
14. “hepatitis c” in Trials
15. hcv in Trials
16. #12 or #13 or #14 or #15
17. MeSH descriptor: [Cross Infection] explode all trees
18. MeSH descriptor: [Infection Control] explode all trees
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19. MeSH descriptor: [Universal Precautions] explode all trees
20. infection control* in Trials
21. isolat* in Trials
22. #17 or #18 or #19 or #20 or #21
23. #6 and #11 and #16 and #22
MEDLINE 1. Renal Dialysis/
2. exp Hemofiltration/
3. dialysis.tw.
4. (hemodialysis or haemodialysis).tw.
5. (hemofiltration or haemofiltration).tw.
6. (hemodiafiltration or haemodiafiltration).tw.
7. or/1-6
8. Hemodialysis Units, Hospital/
9. ((hemodialysis$ or haemodialysis$ or dialysis$) and (centre$ or centre$ or unit$ or department$ or hospital$ or
facilit$ or clinic$)).tw.
10. ambulatory care facilities/ or outpatient clinics, hospital/
11. or/8-10











23. 7 and 11 and 16 and 22
EMBASE 1. hemodialysis/














15. 4 and 9 and 14
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Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias: Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
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Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias: No blinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion of missing outcomes compared with observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
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High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Appendix 3. Risk of bias assessment tool for cluster randomised studies
Potential source of bias Assessment criteria
Was recruitment bias adequately prevented? Low risk of bias: Individuals were not recruited to the trial after
the clusters had been randomised
High risk of bias: Individuals were recruited to the trial after the
clusters had been randomised (the knowledge of whether each
cluster is an ‘intervention’ or ‘control’ cluster could affect the types
of participants recruited)
Unclear risk of bias: Insufficient information to permit judgement.
Were baseline imbalances (in terms of either the clusters or
the individuals) adequately addressed?
Low risk of bias: The randomised groups were similar at baseline;
or the randomised groups were imbalanced at baseline but finally
controlled for at the design (such as using stratified or pair matched
randomisation of clusters) or analysis stage of the study
High risk of bias: There were baseline imbalances between the
randomised groups, but finally they were not controlled for at the
design or analysis stage of the study
Unclear risk of bias: Insufficient information to permit judgement.
Were loss of clusters and participants adequately addressed? See Appendix 2: “Incomplete outcome data” for criteria of how
we will assess this domain
Was the study analysed by correct statistical methods (i.e. tak-
ing the clustering into account)?
Low risk of bias: The cluster-randomised trial was analysed by cor-
rect statistical methods, taking the clustering into account. Ways
to avoid unit-of-analysis errors in cluster-randomised trials are
(see Cochrane Handbook 16.3.3, Higgins 2011b): to conduct the
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analysis at the same level as the allocation; to conduct the analysis
at the level of the individual while accounting for the clustering in
the data. Such an analysis might be based on a ‘multilevel model’,
a ‘variance components analysis’ or a ‘generalized estimating equa-
tions (GEEs)’, among other techniques
High risk of bias: The cluster-randomised trial was analysed by in-
correct statistical methods, not taking the clustering into account.
Such analyses tend to create a ‘unit of analysis error’ and produce
over-precise results (the standard error of the estimated interven-
tion effect is too small) and P values that are too small. Although
they do not lead to biased estimates of effect, if they remain un-
corrected, they will receive too much weight in a meta-analysis
Unclear risk of bias: insufficient information to permit judgement.
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• None known, Peru.
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• No sources of support supplied
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Additional risk of bias assessments have been added due to the inclusion of cluster RCTs.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Hepacivirus; ∗Patient Isolation; ∗Renal Dialysis [instrumentation]; Hepatitis C [epidemiology; ∗prevention & control; transmission];
Incidence; Randomized Controlled Trials as Topic
MeSH check words
Humans
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